These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17633094)

  • 1. [Current status and future perspectives of the Glivec Registration System established by JSCH/JSH-TARGET].
    Kizaki M;
    Rinsho Ketsueki; 2007 Jun; 48(6):468-74. PubMed ID: 17633094
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 3. Introduction: chronic myelogenous leukemia (CML).
    Jabbour E; Kantarjian H
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S1-3. PubMed ID: 17292735
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 5. Hope for leukemia.
    Lichtman MA
    Health News; 2001 Jan; 7(1):3. PubMed ID: 11198409
    [No Abstract]   [Full Text] [Related]  

  • 6. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 7. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STI-571: current status and future prospects.
    Schiffer CA
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1279-81. PubMed ID: 11717816
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
    [No Abstract]   [Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract]   [Full Text] [Related]  

  • 14. Exploiting oxidative damage to overcome resistance.
    Karp JE; Smith BD
    Leuk Res; 2006 Oct; 30(10):1213-4. PubMed ID: 16564572
    [No Abstract]   [Full Text] [Related]  

  • 15. Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH.
    Kizaki M; Okamoto S; Tauchi T; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y;
    Int J Hematol; 2008 Nov; 88(4):409-417. PubMed ID: 18953513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).
    Tsapas A; Vlachaki E; Sarigianni M; Klonizakis F; Paletas K
    Leuk Res; 2008 Apr; 32(4):674-5. PubMed ID: 17920117
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M; Ristic S; Pavlovic S; Colovic M
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
    Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
    Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.